{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:09:00Z","timestamp":1784092140136,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Naomi Prawer Kadar MD-PhD Fellowship and the Yoran Institute for Human Genome Research at Tel Aviv University"},{"name":"StG ERC grant","award":["101040267-GeneCKD"],"award-info":[{"award-number":["101040267-GeneCKD"]}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"crossref","award":["3911\/24"],"award-info":[{"award-number":["3911\/24"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kaylie and Beutler family foundations"},{"name":"Vertex Pharmaceuticals Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05006-9","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:55:39Z","timestamp":1777888539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report of a child with kidney disease: consideration of the risk of a single APOL1 G2 allele with a protective N264K variant on the G0 parental chromosome"],"prefix":"10.1186","volume":"27","author":[{"given":"Meidad","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Tabachnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Ben-Ruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Vivante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Skorecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"5006_CR1","doi-asserted-by":"publisher","unstructured":"Ojo AO, Adu D, Bramham K, Freedman BI, Gbadegesin RA, Ilori TO, et al. APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;8(5). https:\/\/doi.org\/10.1016\/j.kint.2025.05.017.","DOI":"10.1016\/j.kint.2025.05.017"},{"key":"5006_CR2","doi-asserted-by":"publisher","unstructured":"Larsen CP, Beggs ML, Saeed M, Ambruzs JM, Cossey LN, Messias NC, et al. Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Mod Pathol. 2015;28(1). https:\/\/doi.org\/10.1038\/modpathol.2014.92.","DOI":"10.1038\/modpathol.2014.92"},{"key":"5006_CR3","doi-asserted-by":"publisher","unstructured":"Vivante A. Genetics of chronic kidney disease. N Engl J Med. 2024;391(7). https:\/\/doi.org\/10.1056\/NEJMra2308577.","DOI":"10.1056\/NEJMra2308577"},{"key":"5006_CR4","doi-asserted-by":"publisher","unstructured":"Gupta Y, Friedman DJ, Mcnulty M, Khan A, Lane B, Wang C, et al. Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nat Commun. 2023;14(1). https:\/\/doi.org\/10.1038\/s41467-023-43020-9.","DOI":"10.1038\/s41467-023-43020-9"},{"key":"5006_CR5","doi-asserted-by":"publisher","unstructured":"Hung AM, Assimon VA, Chen H, chang, Yu Z, Vlasschaert C, Triozzi JL, et al. Genetic inhibition of APOL1 pore-forming function prevents APOL1-mediated kidney disease. J Am Soc Nephrol. 2023;34(11). https:\/\/doi.org\/10.1681\/ASN.0000000000000219.","DOI":"10.1681\/ASN.0000000000000219"},{"key":"5006_CR6","doi-asserted-by":"publisher","unstructured":"Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Engl J Med. 2023;388(11). https:\/\/doi.org\/10.1056\/nejmoa2202396.","DOI":"10.1056\/nejmoa2202396"},{"key":"5006_CR7","doi-asserted-by":"publisher","unstructured":"Tabachnikov O, Skorecki K, Kruzel-Davila E. APOL1 nephropathy \u2013 a population genetics success story. Curr Opin Nephrol Hypertens. 2024;33(4). https:\/\/doi.org\/10.1097\/MNH.0000000000000977.","DOI":"10.1097\/MNH.0000000000000977"},{"key":"5006_CR8","doi-asserted-by":"publisher","unstructured":"Gbadegesin RA, Ulasi I, Ajayi S, Raji Y, Olanrewaju T, Osafo C, et al. APOL1 bi- and monoallelic variants and chronic kidney disease in West Africans. N Engl J Med. 2025;392(3). https:\/\/doi.org\/10.1056\/NEJMoa2404211.","DOI":"10.1056\/NEJMoa2404211"},{"key":"5006_CR9","doi-asserted-by":"publisher","unstructured":"Tassiopoulos KK, Wu K, Wu Z, Overton ET, Palella FJ, Wyatt C, et al. APOL1 genotype and HIV infection: 20-year outcomes for CKD, cardiovascular disease, and hypertension. Kidney Int Rep. 2025;10(3). https:\/\/doi.org\/10.1016\/j.ekir.2024.12.022.","DOI":"10.1016\/j.ekir.2024.12.022"},{"key":"5006_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-026-04789-1","author":"E van Schijndel","year":"2026","unstructured":"van Schijndel E, Roelofs J, Hilhorst M, Bemelman F. Collapsing FSGS in a kidney transplant with a single APOL1 risk variant: a case report. BMC Nephrol. 2026. https:\/\/doi.org\/10.1186\/s12882-026-04789-1.","journal-title":"BMC Nephrol"},{"key":"5006_CR11","doi-asserted-by":"publisher","unstructured":"Acharya R, Upadhyay K. Early recurrence of focal segmental glomerulosclerosis in a kidney transplant recipient with APOL1 one risk variant. BMJ Case Rep. 2023;16(5). https:\/\/doi.org\/10.1136\/bcr-2023-254593.","DOI":"10.1136\/bcr-2023-254593"},{"key":"5006_CR12","doi-asserted-by":"publisher","unstructured":"Ben-Ruby D, Atias-Varon D, Kagan M, Chowers G, Shlomovitz O, Slabodnik-Kaner K, et al. Multiethnic prevalence of the APOL1 G1 and G2 variants among the Israeli dialysis population. Clin Kidney J. 2025;18(2). https:\/\/doi.org\/10.1093\/ckj\/sfae397.","DOI":"10.1093\/ckj\/sfae397"},{"key":"5006_CR13","doi-asserted-by":"publisher","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4). https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"5006_CR14","doi-asserted-by":"publisher","unstructured":"Scales SJ, Gupta N, Mazi\u00e8re AM, De, Posthuma G, Chiu CP, Pierce AA, et al. Apolipoprotein L1-specific antibodies detect endogenous APOL1 inside the endoplasmic reticulum and on the plasma membrane of podocytes. J Am Soc Nephrol. 2020;31. https:\/\/doi.org\/10.1681\/ASN.2019080829.","DOI":"10.1681\/ASN.2019080829"},{"key":"5006_CR15","doi-asserted-by":"publisher","unstructured":"Lannon H, Shah SS, Dias L, Blackler D, Alper SL, Pollak MR, et al. Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background. Kidney Int. 2019;96(6). https:\/\/doi.org\/10.1016\/j.kint.2019.07.010.","DOI":"10.1016\/j.kint.2019.07.010"},{"key":"5006_CR16","doi-asserted-by":"publisher","unstructured":"Lan X, Wen H, Lederman R, Malhotra A, Mikulak J, Popik W, et al. Protein domains of APOL1 and its risk variants. Exp Mol Pathol. 2015;99(1). https:\/\/doi.org\/10.1016\/j.yexmp.2015.06.003.","DOI":"10.1016\/j.yexmp.2015.06.003"},{"key":"5006_CR17","doi-asserted-by":"publisher","unstructured":"O\u2019Toole JF, Schilling W, Kunze D, Madhavan SM, Konieczkowski M, Gu Y, et al. ApoL1 overexpression drives variant-independent cytotoxicity. J Am Soc Nephrol. 2018;29(3). https:\/\/doi.org\/10.1681\/ASN.2016121322.","DOI":"10.1681\/ASN.2016121322"},{"key":"5006_CR18","doi-asserted-by":"publisher","unstructured":"Gupta N, Waas B, Austin D, Mazi\u00e8re AM, De, Kujala P, Stockwell AD, et al. Apolipoprotein L1 (APOL1) renal risk variant \u2013 mediated podocyte cytotoxicity depends on African haplotype and surface expression. Sci Rep. 2024;14(1). https:\/\/doi.org\/10.1038\/s41598-024-53298-4.","DOI":"10.1038\/s41598-024-53298-4"},{"key":"5006_CR19","doi-asserted-by":"publisher","unstructured":"Brugnano R, Del Sordo R, Covarelli C, Gnappi E, Pasquali S. IgM nephropathy: Is it closer to minimal change disease or to focal segmental glomerulosclerosis? J Nephrol. 2016;29(4). https:\/\/doi.org\/10.1007\/s40620-016-0269-6.","DOI":"10.1007\/s40620-016-0269-6"},{"key":"5006_CR20","doi-asserted-by":"publisher","unstructured":"Agrawal G, Agarwal B, Sonavane K, Shirsat P. Immunoglobulin M nephropathy: a diagnostic dilemma between minimal change disease and focal segmental glomerulosclerosis. Cureus. 2025;17(5). https:\/\/doi.org\/10.7759\/cureus.84148.","DOI":"10.7759\/cureus.84148"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05006-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:54:18Z","timestamp":1784091258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05006-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5006"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05006-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In accordance with the Declaration of Helsinki, a waiver was granted by the Institutional Review Board at the Meir Medical Center for this retrospective case report on the basis of patient anonymity.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient\u2019s parents for publication of this case report and accompanying images, and such signed consent is and will be maintained on file in the offices of author MG.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"429"}}